KURA Stock Analysis: Kura Oncology | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.042m USD | 12M Return: 77.7% | US50127T1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kura Oncology is a clinical-stage biopharmaceutical company headquartered in San Diego, California, that focuses on developing precision medicines for cancer. Its lead commercial product, KOMZIFTI (ziftomenib), is an oral, selective menin inhibitor, and the company is advancing a broader pipeline that includes Darlifarnib, a Phase 1 farnesyl transferase inhibitor being studied in solid tumors, and KO-7246, a next-generation menin inhibitor being explored in diabetes and cardiometabolic disorders alongside additional menin inhibitor combinations for solid tumors.
As a clinical-stage oncology company, Kura operates within the biotechnology sub-industry, where firms typically rely on capital markets, partnerships, and licensing arrangements to fund long drug development cycles before products generate meaningful revenue. Its lead asset targets the menin protein pathway, which has emerged as a clinically validated target in certain genetically defined leukemias, and the company is seeking to extend this mechanism into solid tumor and non-oncology indications.
- KOMZIFTI commercial launch drives first product revenue ramp
- Darlifarnib and KO-7246 pipeline data readouts near term
- Menin inhibitor competitive landscape intensifies with new approvals
| Net Income: -296.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.44 > 0.02 and ΔFCF/TA -19.97 > 1.0 |
| NWC/Revenue: 571.4% < 20% (prev 663.9%; Δ -92.54% < -1%) |
| CFO/TA -0.19 > 3% & CFO -111.8m > Net Income -296.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.9m) vs 12m ago 1.45% < -2% |
| Gross Margin: 94.13% > 18% (prev 99.24%; Δ -5.10% > 0.5%) |
| Asset Turnover: 12.16% > 50% (prev 12.20%; Δ -0.04% > 0%) |
| Interest Coverage Ratio: -208.2 > 6 (EBIT TTM -295.7m / Interest Expense TTM 1.42m) |
| A: 0.75 (Total Current Assets 559.4m - Total Current Liabilities 118.2m) / Total Assets 587.8m |
| B: -2.24 (Retained Earnings -1.32b / Total Assets 587.8m) |
| C: -0.47 (EBIT TTM -295.7m / Avg Total Assets 635.1m) |
| D: 0.09 (Book Value of Equity 48.4m / Total Liabilities 539.4m) |
| Altman-Z'' = -5.41 = D |
| DSRI: 2.23 (Receivables 9.45m/4.57m, Revenue 77.2m/83.3m) |
| GMI: 1.05 (GM 99.24% / 94.13%) |
| AQI: 1.51 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 0.93 (Revenue 77.2m / 83.3m) |
| TATA: -0.31 (NI -296.8m - CFO -111.8m) / TA 587.8m) |
| Beneish M = -1.75 (Cap -4..+1) = CCC |
As of August 26, 2026, the stock is trading at USD 13.59 with a total of 5,348,288 shares traded. Over the past week, the price has changed by +10.22%, over one month by +33.89%, over three months by +30.55% and over the past year by +77.65%.
Current recommended Stop Loss: 12.70 (which is 6.5% or 1.3 ATR below the current price).
Kura Oncology has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy KURA.
- StrongBuy: 10
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 32 | 135.5% |
P/S = 13.4895
P/B = 23.0066
Revenue TTM = 77.2m USD
EBIT TTM = -295.7m USD
EBITDA TTM = -292.4m USD
Long Term Debt = 9.71m USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.51m USD (from shortTermDebt, last quarter)
Debt = 39.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.5m
Net Debt = -33.9m USD (calculated: Debt 39.0m - CCE 72.9m)
Enterprise Value = 1.01b USD (1.04b + Debt 39.0m - CCE 72.9m)
Interest Coverage Ratio = -208.2 (Ebit TTM -295.7m / Interest Expense TTM 1.42m)
EV/FCF = -3.86x (Enterprise Value 1.01b / FCF TTM -260.9m)
FCF Yield = -25.89% (FCF TTM -260.9m / Enterprise Value 1.01b)
FCF Margin = -337.9% (FCF TTM -260.9m / Revenue TTM 77.2m)
Net Margin = -384.3% (Net Income TTM -296.8m / Revenue TTM 77.2m)
Gross Margin = 94.13% ((Revenue TTM 77.2m - Cost of Revenue TTM 4.53m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.71 (Enterprise Value 1.01b / Total Assets 587.8m)
Interest Expense / Debt = 3.64% (Interest Expense 1.42m / Debt 39.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -233.6m (EBIT -295.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.64 (Total Current Assets 559.4m / Total Current Liabilities 120.6m)
Debt / Equity = 0.80 (Debt 39.0m / totalStockholderEquity, last quarter 48.4m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -33.9m / EBITDA -292.4m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -33.9m / FCF TTM -260.9m)
Total Stockholder Equity = 143.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.73% (Net Income -296.8m / Total Assets 587.8m)
RoE = -207.2% (Net Income TTM -296.8m / Total Stockholder Equity 143.2m)
RoCE = -193.3% (out of range, set to none) (EBIT -295.7m / Capital Employed (Equity 143.2m + L.T.Debt 9.71m))
RoIC = -49.57% (negative operating profit) (NOPAT -233.6m / Invested Capital 471.2m)
WACC = 9.13% (E(1.04b)/V(1.08b) * Re(9.36%) + D(39.0m)/V(1.08b) * Rd(3.64%) * (1-Tc(0.21)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.49 | Cagr: 2.58%
[DCF] Fair Price = unknown (Cash Flow -260.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.81 | Chg30d=+10.48% | Revisions=+25% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.23 | Chg30d=+6.70% | Revisions=+25% | GrowthEPS=-1.4% | GrowthRev=+48.2%
EPS next Year (2027-12-31): EPS=-2.30 | Chg30d=+11.46% | Revisions=+40% | GrowthEPS=+28.7% | GrowthRev=+115.0%
[Analyst] Revisions Ratio: +57% (up=4, down=0)